Explore
Trendline
Innate Pharma Reports Q1 2026 Business Update and Financial Results
Innate Pharma Reports Q1 2026 Business Update and Financial Results
Read More
Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026
Read More
Trendline
Longeveron Reports Q1 Financial Results and Strategic Updates
Longeveron Reports Q1 Financial Results and Strategic Updates
Read More
Trendline
Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments
Spruce Biosciences Reports Q1 2026 Financial Results and Strategic Developments
Read More
Trendline
Affinia Therapeutics Presents Promising Data for Gene Therapy in Cardiomyopathy
Affinia Therapeutics Presents Promising Data for Gene Therapy in Cardiomyopathy
Read More
Trendline
Imunon, Inc. Reports Increased Net Loss in Q1 2026 Amid Clinical Advancements
Imunon, Inc. Reports Increased Net Loss in Q1 2026 Amid Clinical Advancements
Read More
Trendline
Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates
Turn Therapeutics Reports Q1 2026 Financial Results and Corporate Updates
Read More
Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Read More
Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Read More
Trendline
AN2 Therapeutics Reports Q1 2026 Financial Results and Pipeline Updates
AN2 Therapeutics Reports Q1 2026 Financial Results and Pipeline Updates
Read More
Trendline
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Omeros Corporation to Announce First Quarter Financial Results and Host Conference Call
Read More
Trendline
Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026
Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026
Read More
